TurboCHO™ Antibody Expression Service
5 Business Days from Gene to Antibody – Say Goodbye To Waiting
Receive your quote directly from the manufacturer.
GenScript's proprietary TurboCHO™ platform offers high throughput production of purified antibodies, featuring the market's fastest turnaround time—just 5 business days from gene to antibody. With a large capacity of 30,000+ targets/month, TurboCHO™ ensures a seamless production. With premium quality, this platform provides a cost-effective and time-efficient solution for various stages of antibody research, including lead characterization, antibody engineering, humanization, affinity maturation, and more.
Discover more about different TurboCHO™ platforms.
- TurboCHO™ High Throughput: Designed for high-throughput screening, as fast as 5 Business Days
- TurboCHO™ Express: Yield up to gram, starting at 2 weeks
- TurboCHO™ High Performance: Gram-level stable expression from 6-7 weeks
- TurboCHO™ Stable Cell Pool & Cell Line : High expression level with ECACC-Licensed CHO-K1 Cell
Mastering multi-specific antibody production for next-gen drug discovery
The ongoing AI revolution opens up a new era of antibody design, with a focus on bi-specific antibodies. Gain insight into how artificial intelligence (AI) is assisting next-generation drug discovery in the production of multispecific antibodies.
Enhance productivity and purity in next-generation bispecific antibody manufacturing
Monday, July 14, at 15:00 BST | 16:00 CEST | 10:00 EDT | 7:00 PDT
Bispecific antibodies (BsAbs) are at the forefront of next-generation antibody therapies, offering immense potential but also presenting significant production challenges, such as secretion inefficiencies, chain mispairing, and impurity formation.
Join Dr. Heng Tai Liew, Senior Protein Scientist at GenScript Biotech and discover how GenScript's TurboCHO™ technology overcomes these hurdles through an integrated and iterative workflow that optimizes cell lines, vectors, and media using Design of Experiments (DOE) to refine chain ratios and boost yields. This approach is complemented by a both streamlined and customized purification strategy that utilizes advanced chromatography techniques, enabling selective impurity removal based on molecular differences to achieve superior purity.
Real-world case studies validate the efficacy of this systematic method, demonstrating its capacity to resolve common BsAb production obstacles and support a range of formats from early-stage development through to clinical-scale manufacturing.
Key learning objectives:
- Characterize the key challenges in BsAb production, including issues related to secretion efficiency, chain mispairing, and impurity accumulation, and their impact on the scalability and therapeutic potential of next-generation antibody-based therapies.
- Learn how GenScript’s TurboCHO technology optimizes the production process, including the use of DOE-driven cycles to refine cell lines, vectors, media, and chain ratios for improved yields.
- Understand how GenScript leverages chromatography techniques to achieve high-purity bispecific antibodies and effectively address common production challenges from development to clinical application.
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes. If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Meet the winners of the 2022 Scientists’ Choice Awards for Drug Discovery & Development
Scientific, technological, and communications excellence has been celebrated at SLAS2022 with MOBILion Systems, Agilent Technologies, and Wyatt Technology Corp. among those recognized
